Clinical Trial News and Research

RSS

Early treatment for hepatitis C offers a good chance of a cure

Australian researchers say as many as 70% of hepatitis C carriers can possibly be cured of the disease with early treatment - this is excellent news as hepatitis C, if left untreated can lead to serious liver disease.

22 Apr 2009

Experimental agent shows promise for advanced biliary cancer

An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.

21 Apr 2009

Pancreatic cancer cells targeted with combo therapy

A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report.

21 Apr 2009

Pregnancy hormone hCG protects against breast cancer even in short-term treatments

One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.

21 Apr 2009

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

NanoBio has announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

20 Apr 2009

Grapefruit juice boosts efficacy of drug rapamycin

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given.

20 Apr 2009

Fulvestrant influences the effects of chemotherapy drugs on breast cancer cells

Researchers from The Cancer Institute of New Jersey (CINJ) are converging on Denver for the 100th Annual Meeting of the American Association for Cancer Research (AACR) to share their findings on a combined treatment targeting breast cancer that is stimulated by the hormone estrogen (estrogen receptive positive).

20 Apr 2009

Nanoparticle delivery of a fully functioning copy of P53 tumor suppressor gene

Dr. Esther Chang describes the most recent developments in human trials of the first systemic, non-viral, tumor-targeted, nanoparticle method designed to restore normal gene function to tumor cells while completely bypassing normal tissue April 21 at an American Association of Anatomists (AAA) scientific session at Experimental Biology 2009 in New Orleans.

20 Apr 2009

Molecular profiling helps cancer patients survive

Cancer patients can survive longer under treatments based on their individual genetic profiles, according to a nationwide study released jointly today by Phoenix-area healthcare organizations.

20 Apr 2009

Naltrexone appears to relieve fibromyalgia pain

For Tara Campbell, the onset of her fibromyalgia began slowly with repeated sore throats, fevers and fatigue.

20 Apr 2009

Cognitive behavioral therapy helps alleviate nonepileptic seizures

Researchers at Rhode Island Hospital have found that cognitive behavioral therapy (CBT) can reduce the frequency of seizures in patients with psychogenic nonepileptic seizures (PNES), along with improving their overall quality of life.

15 Apr 2009

Rib-X granted patent for novel oxazolidinone in China

Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China.

15 Apr 2009

Vaccine for Coeliac disease could mean the end of gluten free diets

Australian scientists have developed an experimental vaccine to treat coeliac disease. The team at the Walter and Eliza Hall (WEHI) Institute in Melbourne are hoping a phase 1 clinical trial of the vaccine, due to begin this month, will eventually lead to an effective clinical treatment for the disease.

15 Apr 2009

PET/CT imaging shows if single cycle of chemo is working

Oncologists often have to wait months before they can determine whether a treatment is working.

14 Apr 2009

Scientists discover way to jumpstart bone's healing process

Rarely will physicians use the word "miraculous" when discussing patient recoveries.

14 Apr 2009

Rockefeller University Hospital opens clinical trial into statin-associated muscle complaints

The most widely prescribed class of drugs in the country, statins have helped millions of people lower their cholesterol and reduce their risk of heart attacks - but their side effects, including muscle pain and cramping, have proven to be something of a sore point for many patients.

14 Apr 2009

New AIDS research training grants awarded for projects in 15 countries

The Fogarty International Center of the National Institutes of Health has awarded seven grants totaling almost $2.7 million to train HIV/AIDS researchers in 15 low- and middle-income countries.

14 Apr 2009

Hypoglycemic episodes increase dementia risk in seniors with type 2 diabetes

Hypoglycemic (low blood sugar) episodes that require a visit to the hospital are associated with increased risk of dementia in elderly patients with type 2 diabetes mellitus, according to a Kaiser Permanente Division of Research study in the Journal of the American Medical Association.

14 Apr 2009

FDA imposes restrictions on Coast IRB due to violations

The U.S Food and Drug Administration has announced that Coast IRB, LLC of Colorado Springs, Colo., has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company's ability to protect human subjects participating in clinical trials.

14 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009